Fig. 1From: Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension studyEnrollment and follow-up of patients who completed the core 6-month study and entered the long-term extension. A patient was defined as having completed the extension study if he/she was taking part in the study at the time of fingolimod launch in JapanBack to article page